# Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Source: https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/  
OnCo record `paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding a third antibody, directed at a different target, to the usual tablet-and-antibody pairing added about eight months before follicular lymphoma progressed again.

## Summary

A phase 3, double-blind, randomised, placebo-controlled trial at 210 centres in North America, Europe and the Asia-Pacific region. Adults with relapsed or refractory follicular lymphoma after at least one previous line were randomised 1 to 1 to up to twelve 28-day cycles of tafasitamab 12 mg per kilogram intravenously, or placebo, both with lenalidomide 20 mg daily on days 1 to 21 of cycles 1 to 12 and rituximab 375 mg per square metre. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population.

Between 16 April 2021 and 10 August 2023, 548 of 817 patients assessed were enrolled and randomised, 273 to tafasitamab and 275 to placebo; 299 (55 per cent) were male and 249 (45 per cent) female. Median progression-free survival by investigator was 22.4 months (95 per cent confidence interval 19.2 to not evaluable) with tafasitamab against 13.9 months (11.5 to 16.4) with placebo, a hazard ratio of 0.43 (0.32 to 0.58).

## Fields

- Kind: Key paper
- Last checked: 2026-10-01
- Also known as: inMIND; Sehn 2026
- Tags: lymphoma-evidence
- Journal: Lancet
- Year: 2026
- DOI: 10.1016/S0140-6736(25)01778-7
- Authors: Sehn LH, Hübel K, Luminari S, et al.
- Findings: Median investigator-assessed progression-free survival was 22.4 months with tafasitamab, lenalidomide and rituximab against 13.9 months with placebo, lenalidomide and rituximab (hazard ratio 0.43, 95 per cent confidence interval 0.32 to 0.58).; 548 patients were randomised at 210 centres across North America, Europe and the Asia-Pacific region.; The trial was double-blind and placebo-controlled, with patients, investigators and funder masked until the primary analysis.; Eligibility required at least one previous line of systemic therapy, which is a broader population than most relapsed follicular lymphoma trials.
- What it means: A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing, with the largest progression-free survival hazard ratio reported in the setting.
- Caveats: Progression-free survival is the primary endpoint; overall survival data were immature at this analysis.; The comparator, lenalidomide with rituximab, is a reasonable standard, but the trial does not compare against CAR-T or bispecific antibodies, which are the alternatives for early-progressing disease.; Adding a CD19-directed antibody before CAR-T raises a question about subsequent CD19 CAR-T efficacy that the trial does not answer.

## Sources

- Lancet 2026: https://doi.org/10.1016/S0140-6736(25)01778-7
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41360064/
- Europe PMC: https://europepmc.org/article/MED/41360064

## Connected records

- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Incyte](https://onco.cc/companies/incyte/)
- trials: [A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa](https://onco.cc/trials/nct04680052/)
- people: [Laurie H. Sehn](https://onco.cc/people/laurie-sehn/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)
- journals: [The Lancet](https://onco.cc/journals/lancet/)

---
JSON: https://onco.cc/api/v1/entities/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026.json